通用中文 | 重组蛋氨酸人干细胞因子 | 通用外文 | Ancestim |
品牌中文 | 品牌外文 | Stemgen | |
其他名称 | R-metHuSCF | ||
公司 | 安进(Amgen) | 产地 | 美国(USA) |
含量 | 1875mcg | 包装 | 1支/盒 |
剂型给药 | 注射用粉剂 | 储存 | 2度-8度(冰箱冷藏,禁止冷冻) |
适用范围 | 与非格司亭(GCSF)联合提供外周血量的增加,用于将祖细胞从骨髓移动到与GCSF结合的外周血. |
通用中文 | 重组蛋氨酸人干细胞因子 |
通用外文 | Ancestim |
品牌中文 | |
品牌外文 | Stemgen |
其他名称 | R-metHuSCF |
公司 | 安进(Amgen) |
产地 | 美国(USA) |
含量 | 1875mcg |
包装 | 1支/盒 |
剂型给药 | 注射用粉剂 |
储存 | 2度-8度(冰箱冷藏,禁止冷冻) |
适用范围 | 与非格司亭(GCSF)联合提供外周血量的增加,用于将祖细胞从骨髓移动到与GCSF结合的外周血. |
温哥华医院和卫生科学中心
药物服务
非配方药物数据表
___________________________________________________________________________________________________
药物名称替代名称
Ancestim Stemgen -
R-metHuSCF
重组蛋氨酸人干细胞因子
___________________________________________________________________________________________________
制造商
安进
___________________________________________________________________________________________________
强化剂量表格
Ancestim 1875 mcg小瓶冻干粉用于重建
(公司提供1.2ml SWFI)
___________________________________________________________________________________________________
适应症
- 与非格司亭(GCSF)联合使用,以提供外周血量的持续增加
能够植入的祖细胞(PBPC),以增加达到PBPC靶的患者比例和
以减少收集PBPC目标数量所需的通道数量。
- 用于将祖细胞从骨髓移动到与GCSF结合的外周血,用或
没有PBPC动员化疗。
___________________________________________________________________________________________________
用法和用量(查看完整用法说明书的产品单页)
- 每天20微克/千克/天SC
- 不要给IV
- 没有GCSF时不应给予Ancestim,但必须在不同的部位分别注射。
___________________________________________________________________________________________________
已知的副作用*
- 过敏反应,轻度至中度注射部位反应(红斑,瘙痒,荨麻疹,注射时色素沉着过度
站点),骨骼疼痛,咽炎,呼吸困难和咳嗽。
- 在PBPC动员的临床试验中,3%的患者经历了全身过敏样反应,其解决了
同时施用额外的抗组胺剂和/或皮质类固醇
___________________________________________________________________________________________________
特别注意事项
- 将小瓶存放在冰箱中(2-8摄氏度)
- 任何在室温下放置超过72小时的小瓶应该丢弃。
- 重新构成瓶的绝对过期=冰箱内24小时
- 一次性使用小瓶。
- 用1.2mL SWFI重建每个1875微克小瓶以产生1500mcg / ml(1.5mg / ml)的终浓度。
(可抽出量= 1毫升)
- 预防措施:
H1拮抗剂:例如。苯海拉明50mg po q6h或西替利嗪(VGH不提供)每日10mg
2. H2拮抗剂例如。雷尼替丁150mg口服
3.沙丁胺醇吸入器2次预喷30-60分钟
(在第一次注射前12到24小时开始H1和H2拮抗剂,进一步给药应该是定时的
在每次注射前60-90分钟给予剂量。应该持续到最后一次注射后48小时。
___________________________________________________________________________________________________
*向药剂师报告任何不良反应
其他参考资料
STEMGEN®(ancestim)
药物名称
Ancestim是由重组DNA技术产生的人类干细胞因子(SCF)。
STEMGEN®是安进公司(重组甲硫氨酰人干)的Amgen Inc.商标
细胞因子,r-metHuSCF)。
描述
STEMGEN®是由大肠杆菌(Escherichia coli)(大肠杆菌)产生的166个氨基酸的蛋白质
该基因已被插入用于可溶性人干细胞因子。 STEMGEN®有一个单体分子量约为18,500道尔顿,通常以a非共价缔合的二聚体。该蛋白质具有与其相同的氨基酸序列除添加外,从人类DNA序列分析预测的自然序列在大肠杆菌中表达后保留的N-末端甲硫氨酸。因为STEMGEN®是在大肠杆菌中产生,产物非糖基化。STEMGEN®是一种无菌,白色,无防腐剂,冻干粉,用于重建和作为皮下(SC)注射给药。每一次使用STEMGEN®的小瓶
在0.84至1.8×10 6的比活性下含有1.875mg刺激剂 U / mg(如测量通过细胞有丝分裂测定)。将小瓶STEMGEN®用1.2mL无菌溶液重新配制注射用水产生1500μg/ mL的刺激剂浓度。重组STEMGEN®是含有4.5%甘露醇和0.5%蔗糖的无菌水溶液用5mM谷氨酸和10mM组氨酸在pH6.0缓冲。
剂量和给药
STEMGEN®和NEUPOGEN®不应在服用前24小时内使用化疗后24小时(见注意事项)。 STEMGEN®如果没有NEUPOGEN®,则不应施用。但是,STEMGEN®和NEUPOGEN®必须在不同地点分开注射。
STEMGEN®只能在训练有素的医务人员的情况下进行管理有适当的药物和/或必要的设备来治疗危及生命的反应它们发生。应在给药后至少1小时观察患者STEMGEN®。
推荐剂量的STEMGEN®与NEUPOGEN®配合使用,用于动员PBPC是:
只有细胞因子动员STEMGEN®20μg/ kg / day作为SC推注和NEUPOGEN®10μg/ kg / day SC。施用STEMGEN®和NEUPOGEN®直至成分分离完成。在单独的细胞因子动员方案,每日施用STEMGEN®plusNEUPOGEN®在第5天开始每日服用,被认为是安全有效的(见临床经验)。建议每天服用STEMGEN®不超过(见不良反应)。
化疗后动员作为SC推注注射的STEMGEN®20μg/ kg /天和5μg/ kg /日SC的NEUPOGEN®,化疗完成后24小时开始,直至完成单采。白细胞计数上升到≥4×109时开始/ L已经在临床试验中显示安全有效(见临床经验)。它是建议不要超过STEMGEN®的每日剂量(见ADVERSE反应)。
术前用药
接受STEMGEN®的患者必须预先给予H1和H2抗组胺药和支气管扩张剂(β激动剂)。在临床试验中,苯海拉明(50 mg每6小时口服一次)或西替利嗪(每日一次口服10毫克)最常用作治疗H1抗组胺药,雷尼替丁(每12小时口服150毫克或口服300毫克,每日一次)最常用的H2抗组胺药和沙丁胺醇吸入器(2次抽吸,30〜60分钟)在每次注射之前)用作支气管扩张剂。 H1和H2的管理抗组胺剂应在STEMGEN®首次注射前12至24小时开始。进一步给药时间应该在每次给药前60-90分钟给药STEMGEN®注射,并应持续到最后一次注射后48小时。
重组和稀释
STEMGEN®是一种无菌,白色,无防腐剂,冻干粉,适用于SC推注
注射后重建。 STEMGEN®不应该静脉注射给药(参见禁忌症)。
没有信息可用于连续SC输注DW Issue 1(Full)STEMGEN®(ancestim)
重新配制STEMGEN®。 STEMGEN®必须用1.2 mL无菌水重新配制注射。
当用1.2mL无菌注射用水重新配制时,最终浓缩的STEMGEN®是1500μg/ mL。在重建期间,小瓶内容物可能会温和旋转以避免溶解过程中起泡。避免过度或剧烈的鼓动;不要摇。
STEMGEN®必须在重新配制24小时内使用。
每个只使用一个剂量重组小瓶;不要重新进入小瓶。丢弃未使用的部分。不要保存未使用的
药物为以后管理。
应该视觉检查肠外药物产品的颗粒物质给药前变色;如果观察到颗粒或变色,不应使用容器内容物。
药物过量
STEMGEN®的最大耐受剂量与前药一起使用时具有未被确定。然而,在30至30分钟内用STEMGEN®治疗的37名患者中有10名(27%)100μg/ kg /天经历全身性过敏反应。这表明发生率全身性过敏反应可能与剂量有关(见不良反应)。该推荐剂量的STEMGEN®,用于NEUPOGEN®,用于PBPC动员20微克/千克/天。
存储
注射用粉剂:STEMGEN®无菌粉末应存放在冰箱中2°C至8°C(冷藏,不要冷冻)。冻干的STEMGEN®粉末稳定3次天在29°C,没有明显的活性下降或蛋白质完整性的变化。
重组溶液:当用1.2mL无菌注射用水重建时无菌条件下,STEMGEN®在29ºC下稳定24小时,无明显下降在活动或蛋白质完整性的变化。但是,由于微生物的原因,应在重组/制备后尽快使用重组溶液。如果需要储存重组溶液,请保持在2ºC至8ºC(冷藏,不要冻结)不超过24小时。在注射之前,STEMGEN®可能被允许到达室内温度。
介绍
STEMGEN®1.875 mg:分装3个单剂量,不含防腐剂的小瓶含有1.875毫克。
制造商的名称和地址:Amgen Inc.
STEMGEN®
(ANCESTIM)Consumer Medicine Information
What is in this leaflet
This leaflet answers some common questions about Stemgen® . It does not contain all the available information.
It does not take the place of talking to your doctor or pharmacist.
All medicines have risks and benefits. Your doctor has weighed the risks of you taking Stemgen® against the benefits it is expected to have for you.If you have any concerns about taking this medicine, ask your doctor or pharmacist. Read this leaflet carefully before you start Stemgen® and keep it with the medicine.
You may need to read it again.
What Stemgen® is used for
Stemgen® is a man-made form of a naturally- occurring substance which stimulates the growth of certain blood cells called progenitor cells.
These cells are the very early forms of blood cells that mature to become red blood cells, white blood cells and platelets.
Stemgen® is given with another medicine called Neupogen® as an injection under the skin. This increases the number of progenitor cells in the blood (peripheral blood progenitor cells, PBPCs). These cells are then collected from the blood, stored and given back to you after chemotherapy. This procedure is called a PBPC transplant and helps recovery of blood cells after treatment.
There is limited experience with Stemgen® in children. Your doctor will discuss the risks and benefits of using Stemgen® in children.
If you have any questions about using Stemgen® ask your doctor.
Before you receive Stemgen®
You must tell your doctor if:
1. You have ever suffered from asthma or an allergic reaction to any other medicines or any other substances such as foods, preservatives or dyes.
Symptoms of an allergic reaction may include:
· swelling of the face, lips or tongue which may cause difficulty in swallowing or breathing
· asthma, wheezing, shortness of breath
· itching, skin rash or hives
· fainting
2. You have kidney problems.3. You have any type of cancer or tumour, including cancers of the blood, lung or skin (melanoma).
4. You are pregnant or breastfeeding or intend to become pregnant or breastfeed.
Like most medicines, Stemgen® is not recommended during pregnancy or while breastfeeding.Your doctor will discuss the risks and benefits of using Stemgen® .
5. You have any other medical condition.If you have not told your doctor about these things, tell him/her before you start using Stemgen®.
Taking other medicines
Tell your doctor if you are taking any other medicines, including medicines you buy without a prescription from a pharmacy, supermarket or health food shop.
Only limited information is available on possible interactions between Stemgen® and other medicines.
Before you start Stemgen®
When you must not use Stemgen®Do not use Stemgen® if:
1. You have an allergy to Stemgen® , any product prepared using the bacteria E. coli or any of the ingredients listed at the end of this leaflet.
Symptoms of an allergic reaction may include:
· swelling of the face, lips or tongue which may cause difficulty in swallowing or breathing
· asthma, wheezing, shortness of breath
· itching, skin rash or hives
· fainting.
2. You have had chemotherapy or radiotherapy within the last 24 hours or are due to have it in the next 24 hours.It may not be safe to use Stemgen® in the period 24 hours before to 24 hours after chemotherapy and radiotherapy.
3. You have not started using the antihistamines prescribed for you by your doctor within the last 12 to 24 hours or you have not used the inhaler prescribed for you by your doctor in the last 30 to 60 minutes.If you do not use these medicines before starting Stemgen® , you may have a serious allergic reaction to it. See "While you are using Stemgen®" below.
4. The expiry date printed on the pack has passed.5. The powder in the bottle is discoloured or the solution, after it is mixed, is not clear and colourless.
6. The packaging is torn or shows signs of tampering.
While you are using Stemgen®
Things you must do
Make sure you start taking the antihistamines prescribed by your doctor 12 to 24 hours before you receive Stemgen® and continue until 2 days after the last injection of Stemgen®. Follow the doctor's directions for the antihistamines and make sure that you take a dose 60 to 90 minutes before each dose of Stemgen®. You must use the inhaler 30 to 60 minutes before each dose of Stemgen®.
If you do not use these medicines, the risk of having an allergic reaction to Stemgen® is increased.
If you miss a dose of antihistamine, take it as soon as you remember then go back to your normal schedule. Tell your doctor about this missed dose.
How Stemgen® is used
How Stemgen® is injected
Your doctor or nurse will give the injection.
Stemgen® is only given by an injection under the skin. This is called a subcutaneous injection.
If it is accidentally given into a vein, a serious allergic reaction may occur. Your doctor or nurse will have appropriate medication and/or equipment on hand to reverse this reaction.
You will be monitored for an hour after the injection to make sure you do not suffer an allergic reaction.
Stemgen® should not be given without Neupogen® . However, Stemgen® and Neupogen® must be given as separate injections at different sites.
How much is injectedThe usual dose is 20 micrograms of Stemgen® for every kilogram of body weight.Your doctor or nurse will determine exactly how much to inject.
Stemgen® is supplied as a white powder in small glass vials. It is prepared for use by dissolving the powder in 1.2 mL of sterile Water for Injections.
After Stemgen® powder has been dissolved, use the solution as soon as possible (within 1 hour). If the dissolved Stemgen® solution will not be used within 1 hour, it can be stored for up to 24 hours in the refrigerator, between 2°C and 8°C. Do not freeze dissolved Stemgen® solution.When it is injected
The doctor or nurse will give you the Stemgen® injection at about the same time each day.Your doctor will decide when to start using Stemgen and when to stop.
Daily injections will be required for at least 5 days, depending on the response of your blood cells.
If an injection is missedIf a Stemgen® injection is missed, tell your doctor, pharmacist or nurse as soon as possible.If it is still the same day, the missed Stemgen® injection can be given by your doctor or nurse when remembered.
If a complete day is missed, just continue with your normal schedule.
Do not try to make up for a missed Stemgen® injection by taking more than one dose at a time.
If too much Stemgen® is injected (overdose) or it is injected into a vein
Immediately telephone your doctor or Poisons Information Centre for advice (in Australia- telephone 13 11 26; in New Zealand-03 4747
000) or go to Emergency at your nearest hospital if you think you have received too much Stemgen® or it has been injected into a vein. Do this even if there are no signs of discomfort or poisoning. You may need urgent medical attention.
If too much Stemgen® has been injected or it goes into a vein, you may have a serious allergic reaction.
Side effects
Check with your doctor as soon as possible if you have any problems while using Stemgen®, even if you do not think the problems are connected with the medicine or are not listed in this leaflet.
Like other medicines, Stemgen® can cause some side effects. Some side effects may be serious and need medical attention. Other side effects are minor and likely to be temporary.
Ask your doctor or pharmacist any questions you may have.A small number of people (about 3 in 100) experience a generalised allergic reaction.
Tell your doctor immediately or go to Emergency at your nearest hospital if you notice any of the following. Do not have another dose of Stemgen®.· swelling of the face, lips or tongue which may cause difficulty in swallowing or breathing
· asthma, wheezing, shortness of breath
· sudden or severe itching at a place other than the injection site, widespread skin rash or hives
· tight throat or hoarseness
· dizziness or lightheadedness
These symptoms may be serious and could possibly become life-threatening if not treated promptly.
Nearly all people experience redness, itching or swelling at the site of injection of Stemgen® and many people experience bone pain.
Some people have experienced:
· redness, itching, a hives-like rash at the injection site
· darkening of the skin at the injection site which may last several weeks or months
· itching, rash or hives on other parts of the body
· numbness, headache
· feeling sick (nausea)
· fast heart beat
· mild cough, sore throat
Other side effects not listed above may occur in some people.
Tell your doctor if you notice anything that worries you or that is making you feel unwell, even if it is not on this list.
After using Stemgen®
Storage
Stemgen® and needles should be kept where young children cannot reach them.
A locked cupboard at least 11/2 metres above the ground is a good place to store the syringes, needlesand puncture-proof disposal container.
Stemgen® should be kept in a refrigerator between 2° and 8°C. It should not be frozen or left in direct sunlight.Disposal
The doctor or nurse will place all used syringes and needles into a special, puncture-proof disposal container.
Your doctor or pharmacist will dispose of the used Stemgen® vial.
Product description
What it looks like
Stemgen® is supplied as a white powder or "cake" in small glass vials.
IngredientsActive ingredientThe active ingredient in Stemgen® is ancestim.
The pack contains 3-single use vials, each containing 1.875 mg ancestim. The box has a pink stripe and purple dot.
Other ingredients· mannitol 4.5%
· sucrose0.5%
· glutamic acid 5 mM
· histidine 10 mM
Stemgen® is free from preservatives.
SupplierStemgen® is supplied in Australia by:
Invida Australia Pty LtdLevel 8, 67 Albert Avenue
CHATSWOOD NSW 2067
ABN 62 116 935 758
Australian Registration Number:Stemgen® 1.875mg - AUST R 98715
Stemgen® is a registered trademark of Biovitrum AB (publ). This leaflet was prepared on 16 March 2010